08:00 , Feb 23, 2015 |  BC Week In Review  |  Financial News

Merganser Biotech completes venture financing

Merganser Biotech Inc. , Newtown Square, Pa.   Business: Hematology   Date completed: 2015-02-19   Type: Venture financing   Raised: $28 million   Investors: Novartis Venture Funds; Frazier Healthcare; Sutter Hill Ventures; Osage University Partners;...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Financial News

Merganser Biotech completes venture financing

Merganser Biotech Inc. , Newtown Square, Pa.   Business: Hematology   Date completed: 2015-02-19   Type: Venture financing   Raised: $28 million   Investors: Novartis Venture Funds; Frazier Healthcare; Sutter Hill Ventures; Osage University Partners;...
08:00 , Feb 23, 2015 |  BioCentury  |  Finance

Catching up in beta thalassemia

Despite impressive data from more advanced therapies in beta thalassemia, investors in Merganser Biotech Inc. think there's still a role for the biotech's hepcidin replacement therapy in patients with less severe disease. The hematology play...
02:18 , Feb 20, 2015 |  BC Extra  |  Financial News

Merganser raises $28M in series A

Hematology play Merganser Biotech Inc. (Newtown Square, Pa.) raised $28 million in a series A round led by new investor Novartis Venture Fund. New investors Frazier Healthcare; Sutter Hill Ventures; Osage University Partners; and existing...
07:00 , Sep 29, 2014 |  BioCentury  |  Emerging Company Profile

Ossianix: Shark teeth

Ossianix Inc. is developing small shark-derived single domain antibodies that could access hard to hit neuronal targets. The company is working with H. Lundbeck A/S to develop specific inhibitors of pain target P2X3 and to...
08:00 , Feb 25, 2013 |  BioCentury  |  Emerging Company Profile

Merganser: Hip to Hep

Merganser Biotech Inc. is working on a treatment for beta thalassemia that can reduce the toxic accumulation of iron. The company expects using peptide mimetics to regulate iron absorption will be more effective than mopping...
07:00 , Sep 3, 2012 |  BioCentury  |  Finance

Meat of the matter

Meat of the matter Novira Therapeutics Inc. 's $23 million series A round will allow the company to move its discovery-stage viral capsid assembly inhibitor through Phase II trials in HBV, according to Canaan Partners'...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Financial News

Novira completes venture financing

Novira Therapeutics Inc. , Radnor, Pa.   Business: Infectious   Date completed: 8/24/12   Type: Venture financing   Raised: $23 million   Investors: 5AM Ventures; Canaan Partners; WuXi PharmaTech; BioAdvance; Mid-Atlantic Angel Group; Robin Hood...
00:04 , Aug 25, 2012 |  BC Extra  |  Financial News

Novira raises $23M in series A

Novira Therapeutics Inc. (Radnor, Pa.) raised $23 million in a series A round co-led by new investors 5AM Ventures and Canaan Partners. New investor WuXi PharmaTech Inc. (NYSE:WX) also participated, along with existing investors BioAdvance;...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Financial News

Anakim Biologics completes venture financing

Anakim Biologics LLC , Exton, Pa.   Business: Biomanufacturing   Date completed: 6/18/12   Type: Venture financing   Raised: $50,000   Investor: BioAdvance  ...